Package Insert: Information for the Patient
Nebivolol Viatris 5 mg Tablets EFG
Read this package insert carefully before starting to take this medication,because it contains important information for you.
-This medication has been prescribedonlyfor you and should not be given to others, even if they have the same symptomsas you,as it may harm them.
Nebivolol belongs to a group of medicines called selective beta-blockers that is used to lower blood pressure.
Nebivolol is indicated for the treatment of:
Do not take Nebivolol Viatris if:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Nebivolol Viatris if:
Taking Nebivolol Viatris with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
Do not take nebivolol if you are taking any medication that contains flecainide or sultopride (see section “Do not take Nebivolol Viatris if”).
The administration of nebivolol with any of the following medications may reduce your blood pressure too much or cause heart problems:
Also:
Surgery
Nebivolol may interact with certain anesthetics used in operations. If you require any type of surgical intervention, inform your doctor, dentist, or hospital staff that you are taking nebivolol.
Pregnancy and breastfeeding
Nebivolol should not be administered to pregnant women or breastfeeding mothers unless the benefits of administering the medication to the mother outweigh the risks to the fetus or baby.
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
When driving vehicles or operating machinery, be aware that dizziness and fatigue due to decreased blood pressure may occur. In these cases, do not drive or operate machinery. These effects are more likely to occur at the beginning of treatment or after a dose increase (see also section 4).
Nebivolol Viatris contains lactose and sodium
If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Always check that you have enough tablets and that you will not run out of medication. Try to take the tablets at the same time every day. The tablets should be taken with a glass of water. The tablets can be taken with or without food.
The tablet can be divided into 4 equal doses.
Hypertension treatment:
Use in adults:The usual dose is 5 mg of nebivolol per day. The blood pressure-lowering effect is evident after 1-2 weeks of treatment. In some cases, the optimal effect is only achieved after 4 weeks of treatment.
Older patients:If you are 65 years or older and take nebivolol to reduce your blood pressure, the usual starting dose is 2.5 mg per day. If necessary, your doctor may increase your dose to 5 mg of nebivolol per day.
Patients with renal insufficiency:The recommended initial dose is 2.5 mg of nebivolol per day. If necessary, your doctor may increase your dose to 5 mg of nebivolol per day.
Taking Nebivolol Viatris with other medication to lower blood pressure:
The usual daily dose of nebivolol is 5 mg if taken with hydrochlorothiazide, in doses of 12.5 mg-25 mg per day.
Heart failure treatment:
Use in adults and older patients:Your doctor will start treatment with a low dose that will gradually increase in intervals of 1 to 2 weeks until your condition stabilizes. Initially, you will be administered 1.25 mg of nebivolol for one or two weeks, increasing to 2.5 mg of nebivolol once a day, followed by 5 mg once a day, and then 10 mg once a day. Your doctor will inform you of the amount you should take.
Patients with renal insufficiency:
Neurobivolol is not recommended for use in patients with severe renal insufficiency. Your doctor will indicate if you should take nebivolol.
Patients with liver insufficiency:
If you have liver insufficiency, you should not take nebivolol.
Use in children and adolescents:
Neurobivolol is not recommended for use in children and adolescents under 18 years old.
If you take more Nebivolol Viatris than you should:
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount taken.
An accidental overdose could lead to a decrease in heart rate, low blood pressure, difficulty breathing, and sudden cardiac problems.
If you forget to take Nebivolol Viatris:
If you forget to take your medication, do not take a double dose to compensate for the missed doses. Take the next regular dose. Contact your doctor if you forget to take several doses.
If you interrupt treatment with Nebivolol Viatris:
If you suddenly stop treatment with nebivolol, you may experience adverse reactions or your condition may worsen. If you interrupt treatment, your doctor will gradually reduce your dose over a period of 2 weeks.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
If you experience any of the following side effects, stop taking nebivolol and immediately inform your doctor or go to the nearest hospital emergency department:
Other possible side effects include:
Frequent (may affect up to 1 in 10 people):
Infrequent (may affect up to 1 in 100 people):
Very rare (may affect up to 1 in 10,000 people):
Unknown frequency (cannot be estimated from available data):
The following side effects have been reported with medications of the same type as nebivolol, so they may also occur with this medicine.The frequency cannot be estimated from available data.
In a clinical study on chronic heart failure, the following side effects were observed:
Very frequent (may affect more than 1 in 10 people):
Frequent (may affect up to 1 in 10 people):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack, box, or label of the bottle after the abbreviation CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Do not take this medication if you detect any discoloration of the tablets.
Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Nebivolol Viatris
The active ingredient is nebivolol. Each tablet contains 5.45 mg of nebivolol hydrochloride equivalent to 5 mg of nebivolol.
The other components are: lactose monohydrate (see section 2 “Nebivolol Viatris contains lactose and sodium”),croscarmellose sodium, cornstarch, polisorbate 80, hypromellose, microcrystalline cellulose, anhydrous colloidal silica, and magnesium stearate.
Appearance of the product and contents of the package
White, oval-shaped tablets, 9.5 mm x 8.5 mm, cross-scored, smooth with beveled edges. Each tablet ismarked with‘N’in the upper left quadrant and a‘L’in the upper right quadrant on one side only.
This medication is available in packages with PVC/PVdC – Alu blisters of 7, 10, 14, 28, 30, 50, 56, 60, 84, 90, 98 or 100 tablets, in opaque plastic bottles of 100 or 500 tablets or perforated single-dose PVC/PVdC – Alu blisters of 28 x 1, 56 x 1, 100 x 1 tablets.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Responsible manufacturer
McDermott Laboratories Limited t/a Gerard Laboratories
35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13
Ireland
Or
Mylan Hungary Kft.
H-2900 Komárom
Mylan utca 1
Hungary
Or
Viatris Santé
1 Rue de Turin
69007 Lyon
France
Further information about this medication can be obtained by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medication is authorized in the member states of the European Economic Area with the following names:
BelgiumNebivolol Mylan 5 mg tabletten
SpainNebivolol Viatris 5 mg comprimidos EFG
FranceNebivolol Viatris Santé 5 mg comprimé quadrisécable
IrelandNelet 5 mg Tablets
ItalyNIVOLON 5 mg compresse
NetherlandsNebivolol Mylan 5 mg tabletten
PortugalNebivolol Mylan 5 mg comprimidos
United KingdomNebivolol 5 mg Tablets
Last review date of this leaflet:January 2023
Further detailed information about this medication is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)https://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.